Farmers' practices, motivators and barriers for adoption of treatments of digital dermatitis in dairy farms.
This study aimed to catalogue the digital dermatitis (DD) treatment practices used by French dairy farmers and to identify the motivators and barriers to the adoption of these treatments. A semi-structured survey was conducted involving 65 farmers in the main dairy production areas of France in the spring of 2009. The different treatment modalities implemented by farmers since the first diagnosis of DD in their herds were described. The reasons for adopting or abandoning these treatments were then investigated based on criteria of perceived effectiveness, labour, time, cost and toxicity related to their use. For individual treatments, farmers used 30 different products, applied through three different routes, for 1 to 21 consecutive days. For collective treatments, farmers used 31 products, applied through four different routes, at a rate ranging from once a day to once a year. Several products, especially antibiotics, were used without observing the manufacturer's instructions. The principal criteria for the adoption of a treatment was the perceived effectiveness in healing DD lesions and in limiting recurrence, while the principal barriers to adopting a treatment were the time and labour required for its application, followed by cost. Topical oxytetracycline treatments applied individually were used and adopted the most. They were perceived to be effective in healing DD lesions. However, these treatments were judged labour and time consuming, particularly when many animals had to be treated. Collective treatments combining formalin and copper sulphate often were applied topically using walk-though footbaths. These treatments often were judged to be insufficiently effective in healing DD lesions, difficult to implement, labour and time consuming and costly. The plethora of DD treatment practices and the misuse of some treatments could suggest that there is a lack of guidelines available to farmers on the optimal use and expected effectiveness of treatments. Clinical trials should be conducted to develop recommendations based on scientific rather than empirical data, and to identify the DD control measures which consume the least amount of time and labour.